Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 9.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 9.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium chloride provides potassium ions (K+) for maintenance of electrolyte balance. Dextrose (glucose) provides caloric support and is metabolized via glycolysis and oxidative phosphorylation. Sodium chloride provides sodium and chloride ions for fluid and electrolyte balance.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Intravenous infusion at a rate not exceeding 10 mEq/hour, typical adult dose 20 mEq once daily or as directed by serum potassium levels.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
The terminal elimination half-life of potassium is approximately 9 hours (range 7–11 hours) in patients with normal renal function. Clinically, this means steady state is achieved after about 45 hours of continuous infusion; half-life is prolonged in renal impairment.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Potassium is primarily excreted renally (about 90%) via glomerular filtration and tubular secretion in the distal nephron; approximately 10% is eliminated in feces via gastrointestinal secretion.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."